Conclusion Of A Non-Exclusive Discount Agreement According To § 130A Para. 8 Sgb V For The Active Ingredient Dupilumab, Atc D11Ah05 For The Period May 1St, 2023 - April 30Th, 2025

  Address - Germany

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 63566544

  Document Type - Tender Notices

Description - § 130a paragraph 8 SGB V enables the health insurance companies and pharmaceutical companies to conclude framework discount agreements for the drugs to be supplied at the expense of the statutory health insurance companies. With regard to the releva nt legal regulations for the award of public contracts, a regular process of active ingredient-related, formal award procedures takes place according to the regulations of the 4th part of the GWB by the DAK-Gesundheit. For pharmaceuticals to be specified by the bidder in Annex 2 to the contract for the above-mentioned active ingredient dupilumab, ATC D11AH05, DAK-Gesundheit intends to conclude drug discount agreements with as many interested phar

Gt Ref Id - 63566544

Deadline - Mar 05, 2025